Recent Developments in Radiotherapy | NEJM Skip to main content NEJM Group Follow Us
Facebook Twitter Instagram YouTube LinkedIn Prepare to become a physician, build your …

Recording of patient-reported outcomes (PROs) enables direct measurement of the
experiences of patients with cancer. In the past decade, the use of PROs has become a …

Immuno-oncology (IO) has required a shift in the established paradigm of toxicity and
response assessment in clinical research. The design and interpretation of cancer clinical …

In chronic hypersensitivity pneumonitis (CHP), lack of improvement or declining lung
function may prompt use of immunosuppressive therapy. We hypothesised that use of …

Importance In cancer clinical trials, symptomatic adverse events (AEs), such as nausea, are
reported by investigators rather than by patients. There is increasing interest to collect …

The pace of innovation in radiation oncology is high and the window of opportunity for
evaluation narrow. Financial incentives, industry pressure, and patients' demand for high …

Head and neck cancers account for approximately 3% of all cancers in the United States
with 62,000 new cases diagnosed annually. The global incidence is approximately 700,000 …

BACKGROUND Patient‐reported toxicities help to appraise the breast cancer treatment
experience. Yet extant data come from clinical trials and health care claims, which may be …

Lung cancer is often associated with a poor quality of life, as reflected by patient-reported
outcome measures (PROMs). The aim of this paper is to describe and compare the PROMs …

Background Erectile dysfunction (ED) after treatment for prostate cancer with radiotherapy
(RT) is well known, and pooled estimates of ED after RT will provide more accurate patient …